Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage Morphine is used for the management of chronic, moderate to severe pain.[A176050] Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.[L5728]
Marketing Status approved; investigational
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
UNII 76I7G6D29C
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual impairment06.02.10.013---
Vomiting07.01.07.0030.066675%
Vomiting projectile07.01.07.0120.000601%-
Weight decreased13.15.01.005--
Wheezing22.03.01.0090.001715%
Withdrawal syndrome08.06.02.012; 19.07.06.0230.003330%-
Yawning22.12.03.037---
Mental status changes19.07.01.0010.006182%-
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.018---
Fibromyalgia15.05.02.002---
Coronary artery dissection02.02.01.004; 12.02.01.035; 24.02.02.0010.000167%-
Infusion site erythema08.02.05.008; 12.07.05.009; 23.03.06.0160.000490%-
Seasonal allergy06.04.01.013; 10.01.04.001; 22.04.04.008---
Performance status decreased08.01.03.0420.000245%-
Brain oedema12.01.10.010; 17.07.02.0030.001615%
Bladder spasm20.02.02.013--
Brain death08.04.01.004; 17.02.03.0030.000223%-
Emotional distress19.04.02.0080.051527%-
Psychomotor skills impaired17.02.10.005; 19.22.01.002---
Balance disorder08.01.03.081; 17.02.02.007---
Bradyphrenia17.03.03.004; 19.10.03.0020.000412%-
Neonatal hypoxia18.04.15.002; 22.11.02.0020.000278%-
Dysstasia08.01.03.089; 15.03.05.011; 17.02.02.012---
Intervertebral disc protrusion15.10.01.004---
Musculoskeletal chest pain15.03.04.012; 22.09.01.001--
Cardiopulmonary failure02.05.01.004; 22.02.06.0040.000167%-
Dyschezia07.02.03.0050.000111%-
Sticky skin23.03.03.019---
Ureteral spasm20.06.01.002---
Respiratory tract congestion22.02.07.003---
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene